FARALLON CAPITAL MANAGEMENT, L.L.C.FARALLON CAPITAL MANAGEMENT, L.L.C.

Institutional investor · Portfolio as of Q2 2025

Top Holdings145 positions

Checking export access…
Activity:
SPYSPY
Unit

State Street Spdr S&P 500 Etf

5.5M$3.4B14.3%$609.57+25.21%
1 qtr
New
98
HYGHYG
PUT

ISHARES TR

18M$1.5B6.1%———
New
—

MICROSOFT CORP

1.7M$869.4M3.7%$297.44+65.59%
27 qtrssince 2018-Q4
Decreased
0

NATERA INC

4.8M$814.6M3.4%$74.59+126.49%
17 qtrssince 2021-Q2
Increased
62

HESS CORP

5.8M$804.2M3.4%——
7 qtrssince 2023-Q4
Increased
62

AON PLC

2M$708.7M3.0%$321.90+10.31%
6 qtrssince 2024-Q1
Increased
74

EXELIXIS INC

16M$706.8M3.0%$19.40+127.16%
27 qtrssince 2018-Q4
Decreased
0

AMAZON COM INC

3M$665.8M2.8%$223.300.00%
1 qtr
New
82

IQVIA HLDGS INC

3.9M$606.9M2.6%$169.89-7.31%
27 qtrssince 2018-Q4
Increased
61

DISNEY WALT CO

4.9M$604.5M2.5%$95.84+27.55%
5 qtrssince 2024-Q2
Decreased
0

SALESFORCE INC

2.1M$575.1M2.4%$228.09+18.34%
23 qtrssince 2019-Q4
Increased
58

THERMO FISHER SCIENTIFIC INC

1.4M$560.8M2.4%$451.60-10.61%
23 qtrssince 2019-Q4
Increased
69

LANTHEUS HLDGS INC

6.7M$550.3M2.3%$84.51-3.58%
10 qtrssince 2023-Q1
Increased
60

ARAMARK

12.9M$540.1M2.3%$28.25+46.54%
19 qtrssince 2020-Q4
Decreased
0

AUTODESK INC

1.7M$540.1M2.3%$294.73+3.53%
3 qtrssince 2024-Q4
Decreased
0

REVOLUTION MEDICINES INC

14.3M$527M2.2%$34.81+6.04%
18 qtrssince 2021-Q1
Increased
57

UNITEDHEALTH GROUP INC

1.6M$504.5M2.1%$449.19-32.77%
10 qtrssince 2023-Q1
Increased
58

TRANSUNION

5.4M$475.6M2.0%$85.96+1.23%
27 qtrssince 2018-Q4
Decreased
0
IBITIBIT
ETF

ISHARES BITCOIN TRUST ETF

7M$429.7M1.8%$50.32+21.64%
4 qtrssince 2024-Q3
Increased
59

BOSTON SCIENTIFIC CORP

4M$427.6M1.8%$54.63+96.60%
20 qtrssince 2020-Q3
Increased
52
$23.8B
AUM
145
Positions
Q2 2025
Filing
HI score · 1.0/5
Quarterly 13F Value Change
+6%Q1'24$17B-0%Q2'24$16.9B+7%Q3'24$18.2B+4%Q4'24$19B-2%Q1'25$18.5B+18%Q2'25$21.9B
Activity profile
$ moved · Q2'25
New45%Increased17%Decreased9%Exited29%
Composition
Equity vs derivatives
Equity92%Puts8%Calls0%
Holding period
Avg 2.4 years
<1Q9%1-4Q23%1-2Y29%2Y+39%

FARALLON CAPITAL MANAGEMENT, L.L.C. manages $23.8B across 145 positions as of Q2 2025. Top holdings: SPY (14.3%), HYG puts (6.1%), MSFT (3.7%). Fund DNA: Balanced Allocator. HoldingsIntel Score: 1/5.0.

Q2 2025 Summary

Active quarter - 18 new positions, 19 exits, 38 increased. Top move: SPY (NEW, conviction 98). Portfolio: $23.8B across 145 positions.

Top holdings by portfolio weight

Total AUM$22B
SPY14.28%
MSFT3.65%
NTRA3.42%
HES3.38%
AON2.98%
EXEL2.97%
AMZN2.80%
IQV2.55%
DIS2.54%
CRM2.42%
Other2.36%

Portfolio allocation by GICS sector

Sectors10
Healthcare34.22%
Unknown26.06%
Technology12.56%
Financial Services9.68%
Communication Services7.75%
Industrials4.80%
Consumer Cyclical3.28%
Real Estate1.35%
Consumer Defensive0.29%
Energy0.01%

Behavioral investing profile

Checking access…
Balanced Allocator- primarily Healthcare, Unknown, Technology
Compare DNA across all funds
7-dimension, SEC 13F-derived research score
Weak(1.0 / 5.0)
Holdings P&L44
Conviction44
Concentration66
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
7Q
BBIOBBIOBRIDGEBIO PHARMA INC
Q4 2024 → Q2 2026+9M shares+$755.7M
7Q
CRNXCRNXCRINETICS PHARMACEUTICALS IN
Q4 2024 → Q2 2026+7.8M shares+$277M
5Q
BSXBSXBOSTON SCIENTIFIC CORP
Q2 2025 → Q2 2026+6.8M shares+$69.5M
Checking access…

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Verify source filings on SEC EDGAR

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used